CL2013000502A1 - Compuestos derivados de-2-(1-(2(2carbonil - etil) bencil) pirrolidin-2il)-n- alquiloxazol -4 carboxamida; uso en el tratamiento de enfermedades involucrada con la respuesta anttinflamatoria en receptores de prostaglandina. - Google Patents

Compuestos derivados de-2-(1-(2(2carbonil - etil) bencil) pirrolidin-2il)-n- alquiloxazol -4 carboxamida; uso en el tratamiento de enfermedades involucrada con la respuesta anttinflamatoria en receptores de prostaglandina.

Info

Publication number
CL2013000502A1
CL2013000502A1 CL2013000502A CL2013000502A CL2013000502A1 CL 2013000502 A1 CL2013000502 A1 CL 2013000502A1 CL 2013000502 A CL2013000502 A CL 2013000502A CL 2013000502 A CL2013000502 A CL 2013000502A CL 2013000502 A1 CL2013000502 A1 CL 2013000502A1
Authority
CL
Chile
Prior art keywords
alkyloxazole
pyrrolidin
carboxamide
carbonyl
benzyl
Prior art date
Application number
CL2013000502A
Other languages
English (en)
Inventor
Jose L Martos
William R Carling
David F Woodward
Jenny W Wang
Jussi J Kangasmetsa
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CL2013000502A1 publication Critical patent/CL2013000502A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/67—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/30—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CL2013000502A 2010-08-20 2013-02-20 Compuestos derivados de-2-(1-(2(2carbonil - etil) bencil) pirrolidin-2il)-n- alquiloxazol -4 carboxamida; uso en el tratamiento de enfermedades involucrada con la respuesta anttinflamatoria en receptores de prostaglandina. CL2013000502A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37540610P 2010-08-20 2010-08-20

Publications (1)

Publication Number Publication Date
CL2013000502A1 true CL2013000502A1 (es) 2014-01-03

Family

ID=44543856

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013000502A CL2013000502A1 (es) 2010-08-20 2013-02-20 Compuestos derivados de-2-(1-(2(2carbonil - etil) bencil) pirrolidin-2il)-n- alquiloxazol -4 carboxamida; uso en el tratamiento de enfermedades involucrada con la respuesta anttinflamatoria en receptores de prostaglandina.

Country Status (18)

Country Link
US (4) US8653118B2 (es)
EP (1) EP2606044B1 (es)
JP (1) JP5934212B2 (es)
KR (1) KR20130092579A (es)
CN (1) CN103119039A (es)
AR (1) AR082492A1 (es)
AU (1) AU2011291614B2 (es)
BR (1) BR112013003884A2 (es)
CA (1) CA2808798C (es)
CL (1) CL2013000502A1 (es)
DK (1) DK2606044T3 (es)
ES (1) ES2485373T3 (es)
MX (1) MX2013002031A (es)
PL (1) PL2606044T3 (es)
RU (1) RU2013111971A (es)
SG (1) SG188245A1 (es)
TW (1) TW201213323A (es)
WO (1) WO2012024559A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8937073B2 (en) 2010-08-20 2015-01-20 Boehringer Ingelheim International Gmbh Disubstituted tetrahydrofuranyl compounds and their use as B1-receptor antagonists
RU2013111971A (ru) 2010-08-20 2014-09-27 Аллерган, Инк. Соединения, действующие на множественные рецепторы простагландина, дающие общую противовоспалительную реакцию
JP2014512392A (ja) * 2011-04-22 2014-05-22 アラーガン インコーポレイテッド 疼痛を治療するための脂肪酸アミド加水分解酵素阻害剤
AU2012258780A1 (en) * 2011-05-25 2013-12-19 Allergan, Inc. Fatty acid amide hydrolase inhibitors for treating pain
PT3022202T (pt) 2013-07-18 2019-09-03 Novartis Ag Inibidores da autotaxina compreendendo um núcleo beteroaromático anel-benzilo-amida-ciclo
CN107723304A (zh) * 2016-08-10 2018-02-23 中国科学院上海生命科学研究院 Prkar2a在炎症消退中的应用
WO2022212326A1 (en) * 2021-03-29 2022-10-06 Halia Therapeutics, Inc. Nek7 inhibitors
EP4480477A4 (en) 2022-02-15 2025-06-18 Kanaph Therapeutics Inc. Pharmaceutical composition for treating cancer, comprising anticancer agent and novel compound having inhibitory activity with respect to prostaglandin e2 receptors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US5280034A (en) * 1991-08-23 1994-01-18 E. R. Squibb & Sons, Inc. Bis-heterocyclic prostaglandin analogs
TW401408B (en) * 1995-07-21 2000-08-11 Fujisawa Pharmaceutical Co Heterocyclic compounds having prostaglandin I2 agonism
GEP20032998B (en) * 1996-04-12 2003-06-25 Searle & Co Substituted Benzenesulfonamide Derivatives as Prodrugs of Cox-2 Inhibitors
AUPQ253199A0 (en) * 1999-08-30 1999-09-23 Fujisawa Pharmaceutical Co., Ltd. Non-prostanoid prostaglandin I2-agonist
US7217725B2 (en) 2000-09-14 2007-05-15 Allergan, Inc. Prostaglandin D2 antagonist
US6511999B2 (en) 2000-09-14 2003-01-28 Allergan, Inc. Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2α antagonists
US7273883B2 (en) 2000-09-14 2007-09-25 Allergan, Inc. Prostaglandin EP4 antagonist
US7045634B2 (en) * 2003-09-05 2006-05-16 Allergan, Inc. Prostamide receptor antagonists
RU2013111971A (ru) 2010-08-20 2014-09-27 Аллерган, Инк. Соединения, действующие на множественные рецепторы простагландина, дающие общую противовоспалительную реакцию

Also Published As

Publication number Publication date
PL2606044T3 (pl) 2014-09-30
US20160068520A1 (en) 2016-03-10
US9085567B2 (en) 2015-07-21
KR20130092579A (ko) 2013-08-20
CA2808798A1 (en) 2012-02-23
MX2013002031A (es) 2013-05-17
EP2606044A1 (en) 2013-06-26
DK2606044T3 (da) 2014-07-21
US9422273B2 (en) 2016-08-23
EP2606044B1 (en) 2014-06-04
CN103119039A (zh) 2013-05-22
US20140249192A1 (en) 2014-09-04
CA2808798C (en) 2020-04-28
US8653118B2 (en) 2014-02-18
TW201213323A (en) 2012-04-01
JP5934212B2 (ja) 2016-06-15
SG188245A1 (en) 2013-04-30
BR112013003884A2 (pt) 2016-06-07
RU2013111971A (ru) 2014-09-27
US20130150417A1 (en) 2013-06-13
US20120077858A1 (en) 2012-03-29
AU2011291614B2 (en) 2016-05-26
JP2013534254A (ja) 2013-09-02
AR082492A1 (es) 2012-12-12
ES2485373T3 (es) 2014-08-13
WO2012024559A1 (en) 2012-02-23
AU2011291614A1 (en) 2013-03-21

Similar Documents

Publication Publication Date Title
SMT201500206B (it) Composti spiro-ossindolici e loro uso come agenti terapeutici
SMT201400008B (it) Uso di betanecolo per il trattamento di xerostomia
HUE039731T2 (hu) l,3-difenilprop-2-én-l-on-származékok alkalmazása májbetegségek kezelésére
BRPI0919295A2 (pt) 1h-benzimidazol-5-carboxamidas como agentes anti-inflamatórios.
BRPI0719210A2 (pt) Uso de compostos espiro-oxindol como agentes terapêuticos
SMT201900656T1 (it) Formulazioni di ketorolac pronte all'uso
IT1395519B1 (it) Pezzo composito, nonche' impiego del pezzo composito
EP2536762A4 (en) INTEGRIN ALPHA V BETA 8 NEUTRALIZING ANTIBODY
CL2013000735A1 (es) Uso de una composicion que comprende compuestos derivados de 1-h-imidazol-4-il sustituido para el tratamiento de enfermedades y condiciones de la piel, tales como rosacea, daño solar cronico, psoriasis, entre otras; kit farmaceutico.
EP2694544A4 (en) MONOCLONAL ANTIBODIES AGAINST INHIBITOR TISSUE FACTOR PATHWAY (TFPI)
CL2014001861A1 (es) Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia.
BRPI0913267A2 (pt) uso do ácido succínico
CL2008000110A1 (es) Uso de compuestos derivados de piranona sustituidos para el tratamiento del sindrome metabolico; y compuestos derivados de piranona sustituidos.
EP2197448A4 (en) dosing schedule
BRPI0815596A2 (pt) Uso de compostos de sulfonanilida como herbicida
CL2012003322A1 (es) Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer.
BRPI0911772A2 (pt) composto, composição farmacêutica, e, uso do composto.
CL2008001795A1 (es) Uso de un antagonista par1 en el tratamiento de la fibrilacion atrial.
BRPI0807804A2 (pt) " arilciclopentenos substituídos como agentes terapêuticos ".
PL2293805T3 (pl) Kompozycja do ssania, do leczenia chorób zapalnych jamy ustnej i gardłowej
BR112013023575A2 (pt) “derivado de octaidrotienoquinolina, composição farmacêutica compreendendo o derivado, e uso destes”
FR2939766B1 (fr) Pylone central d'aeronef.
ITMI20080195A1 (it) Procedimento per la preparazione di solifenacin
BR112012002311A2 (pt) composto, composição farmacêutica, e, uso do composto.
IT1397522B1 (it) Uso di una combinazione per il trattamento dell'osteoartrosi